Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
8.8 USD -10.02% Intraday chart for Lantern Pharma Inc. -2.55% +105.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Lantern Pharma Inc., Q4 2023 Earnings Call, Mar 18, 2024
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284 CI
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR CI
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers CI
Transcript : Lantern Pharma Inc., Q3 2023 Earnings Call, Nov 08, 2023
Lantern Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company CI
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma CI
Lantern Pharma Doses First Patient in Phase 1 Trial of Advanced Solid Tumor Drug Candidate MT
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors CI
Sector Update: Health Care Stocks Mixed Monday Afternoon MT
FDA Clears Lantern Pharma's Investigation New-Drug Application for LP-284 MT
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin?s Lymphomas CI
Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting CI
Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors CI
Lantern Pharma Receives US Patent Allowance Notice for LP-184 to Treat Rare Pediatric Brain Cancer MT
Lantern Pharma Inc. Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT CI
Transcript : Lantern Pharma Inc., Q2 2023 Earnings Call, Aug 09, 2023
Lantern Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed MT
Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas CI
Lantern Pharma Inc.(NasdaqCM:LTRN) added to Russell 3000E Growth Index CI
Lantern Pharma Inc.(NasdaqCM:LTRN) added to Russell Microcap Growth Index CI
Lantern Pharma Gets US FDA Clearance of Investigational New Drug Application for LP-184 MT
Chart Lantern Pharma Inc.
More charts
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.8 USD
Average target price
20.5 USD
Spread / Average Target
+132.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Lantern Pharma Inc. - Nasdaq
  4. News Lantern Pharma Inc.
  5. Lantern Pharma : to Join Forces With Brain Cancer Program at Johns Hopkins to Further Develop Brain Cancer Drug Candidate LP-184